[1] |
SHI QL, WU JY, MAO DW, et al. Study on the effect of Jiedu Huayu formula II on immune reconstitution in patients with chronic acute liver failure[J]. Tradit Chin Drug Res Clin Pharmacol, 2022, 33( 3): 392- 397. DOI: 10.19378/j.issn.1003-9783.2022.03.017.
石清兰, 吴金玉, 毛德文, 等. 解毒化瘀Ⅱ方对慢加急性肝衰竭患者免疫重建的影响[J]. 中药新药与临床药理, 2022, 33( 3): 392- 397. DOI: 10.19378/j.issn.1003-9783.2022.03.017.
|
[2] |
LYU C, MAO DW, QIN Q, et al. Effect of Wenyang Huayu Tuihuang Decoction in the treatment of hepatitis B-related chronic and acute liver failure[J]. China Med Her, 2019, 16( 30): 142- 146.
吕超, 毛德文, 覃倩, 等. 温阳化瘀退黄方治疗乙型肝炎相关慢加急性肝衰竭的效果[J]. 中国医药导报, 2019, 16( 30): 142- 146.
|
[3] |
Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
|
[4] |
Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
|
[5] |
LIU MY, YE YA. Thinking after diagnosis and treatment of a patient with hepatorenal syndrome[J]. Clin J Tradit Chin Med, 2011, 23( 4): 344- 345. DOI: 10.16448/j.cjtcm.2011.04.036.
刘梦阳, 叶永安. 1例肝肾综合征患者诊治后的思考[J]. 中医药临床杂志, 2011, 23( 4): 344- 345. DOI: 10.16448/j.cjtcm.2011.04.036.
|
[6] |
HUANG ZM, HUANG RF, TANG Y, et al. Effects of Sanqi injection on inflammatory initiators and terminators in rats model with adriamycin-induced renal fibrosis[J]. Chin Arch Tradit Chin Med, 2021, 39( 5): 175- 178. DOI: 10.13193/j.issn.1673-7717.2021.05.042.
黄志敏, 黄仁发, 唐宇, 等. 三七注射液对阿霉素肾纤维化大鼠炎症启动因子和终止因子的影响[J]. 中华中医药学刊, 2021, 39( 5): 175- 178. DOI: 10.13193/j.issn.1673-7717.2021.05.042.
|
[7] |
AI LM, DU GS, JIANG FC. Prevention of severe hepatitis hepatorenal syndrome by benzylamine oxazoline Salvia miltiorrhiza and rhubarb[J]. Chin J Integr Tradit West Med Liver Dis, 1991, 1( 2): 33- 34.
艾黎明, 杜功舜, 蒋方才. 苄胺唑啉丹参及大黄预防重症肝炎肝肾综合症[J]. 中西医结合肝病杂志, 1991, 1( 2): 33- 34.
|
[8] |
HE HY, LI H, YANG Y, et al. The protective effects of fructus canarii and puerariae combination treatment on alcohol-induced rat liver injury[J]. J Med Theory Pract, 2015, 28( 12): 1541- 1543. DOI: 10.19381/j.issn.1001-7585.2015.12.001.
何鸿雁, 李华, 杨艳, 等. 青果葛根配伍液对醉酒大鼠肝脏损伤的保护作用研究[J]. 医学理论与实践, 2015, 28( 12): 1541- 1543. DOI: 10.19381/j.issn.1001-7585.2015.12.001.
|
[9] |
SUN WC, ZHOU HP. Clinical observation of puerarin combined with western medicine in treatment of chronic ischemic nephropathy[J]. Hubei J Tradit Chin Med, 2017, 39( 12): 6- 8.
孙文才, 周和平. 葛根素联合西医常规治疗慢性缺血性肾病的临床观察[J]. 湖北中医杂志, 2017, 39( 12): 6- 8.
|
[10] |
LI X, LIU XY, LI BX, et al. Discussion on hepatorenal syndrome from Guan Ge[J]. Lishizhen Med Mater Med Res, 2019, 30( 9): 2214- 2216. DOI: 10.3969/j.issn.1008-0805.2019.09.056.
李霞, 刘西洋, 李白雪, 等. 从关格论肝肾综合征[J]. 时珍国医国药, 2019, 30( 9): 2214- 2216. DOI: 10.3969/j.issn.1008-0805.2019.09.056.
|
[11] |
YI GD, TAN J. Protective effects of schisandrin B on rat model of hepatorenal syndrome and its possible mechanism[J]. J Med Res, 2018, 47( 9): 172- 175. DOI: 10.11969/j.issn.1673-548X.2018.09.041.
易国栋, 谭静. 五味子乙素对肝肾综合征大鼠的保护作用及其机制研究[J]. 医学研究杂志, 2018, 47( 9): 172- 175. DOI: 10.11969/j.issn.1673-548X.2018.09.041.
|
[12] |
ZHAO ZL, KANG HY, ZHANG Z, et al. Clinical observation of Danhong injection combined with terlipressin in the treatment of severe hepatitis complicated with type 2 hepatorenal syndrome[J]. Mod J Integr Tradit Chin West Med, 2018, 27( 15): 1637- 1640. DOI: 10.3969/j.issn.1008-8849.2018.15.012.
赵子龙, 康海燕, 张志, 等. 丹红注射液联合特利加压素治疗重型肝炎合并2型肝肾综合征疗效观察[J]. 现代中西医结合杂志, 2018, 27( 15): 1637- 1640. DOI: 10.3969/j.issn.1008-8849.2018.15.012.
|
[13] |
LEI XQ, WEI HY, TAN RZ, et al. Effects of Huangqi Sanqi Mixture on cisplatin-induced acute kidney injury in mice[J]. Chin Tradit Pat Med, 2022, 44( 4): 1107- 1113. DOI: 10.3969/j.issn.1001-1528.2022.04.012.
雷小琴, 魏何燕, 谭睿陟, 等. 黄芪三七合剂对顺铂诱导小鼠急性肾损伤的影响[J]. 中成药, 2022, 44( 4): 1107- 1113. DOI: 10.3969/j.issn.1001-1528.2022.04.012.
|
[1] | Zhuoga RENZENG, Kangjie YANG, Yongliang LU, Zhixin WANG, Haijiu WANG. Research advances in neutrophil extracellular traps and liver diseases[J]. Journal of Clinical Hepatology, 2024, 40(3): 639-643. doi: 10.12449/JCH240334 |
[2] | Mingqiang ZHU, Xing XIE, Qicheng LIAO, Xiao HE, Youming DING, Xiaohua WANG. Mechanism of cuproptosis and its role in liver diseases[J]. Journal of Clinical Hepatology, 2024, 40(11): 2332-2337. doi: 10.12449/JCH241131 |
[3] | Guiqiang WANG. Application and prospect of cell therapy in clinical treatment of liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(5): 1001-1003. doi: 10.3969/j.issn.1001-5256.2023.05.001 |
[4] | Zhuoran WANG, Bing ZHU, Limei YU, Shaoli YOU. Role of stem cell-derived exosomes in treatment of liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(3): 699-706. doi: 10.3969/j.issn.1001-5256.2023.03.034 |
[5] | Feiyan LI, Minggang WANG, Dewen MAO, Xiongbin GUI. Role of gasdermin D in the pathological progression of liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(3): 707-712. doi: 10.3969/j.issn.1001-5256.2023.03.035 |
[6] | Wenshang CHEN, Jijin ZHU, Shilai LI. Role of thymic stromal lymphopoietin in liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(5): 1175-1178. doi: 10.3969/j.issn.1001-5256.2022.05.042 |
[7] | Weiyu CHEN, Faming SHU, Han WANG, Yanggang CAO, Jin HU, Dewen MAO. Role of the cytochrome P450 family in metabolic-associated liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(9): 2182-2187. doi: 10.3969/j.issn.1001-5256.2022.09.045 |
[8] | Rui CHEN, Zhixin WANG, Haining FAN, Haijiu WANG. Research advances in the role of lymphocyte activation gene-3 in liver-related diseases[J]. Journal of Clinical Hepatology, 2021, 37(4): 977-981. doi: 10.3969/j.issn.1001-5256.2021.04.056 |
[9] | Lihui ZHANG, Minghao LIU, Wenxia ZHAO. Role of lipotoxicity in the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(2): 463-466. doi: 10.3969/j.issn.1001-5256.2021.02.045 |
[10] | Feiyu ZHANG, ADILA·Yakepu, Jinming ZHAO, Yanhang GAO. Mechanism of ferroptosis and its role in liver diseases[J]. Journal of Clinical Hepatology, 2021, 37(6): 1454-1458. doi: 10.3969/j.issn.1001-5256.2021.06.049 |
[11] | XU LiJun, AN XiuQin, LI Yue, LIU JinChun. Research advances in the role of myeloid-derived suppressor cells in liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(12): 2851-2855. doi: 10.3969/j.issn.1001-5256.2020.12.045 |
[12] | XIAO WeiSong, LE YingYu, ZENG ShengLan, TAN XiaoBin, WU Cong, YA ChengYu, MAO DeWen. Role of pyroptosis in liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(12): 2847-2850. doi: 10.3969/j.issn.1001-5256.2020.12.044 |
[13] | Wang ShaSha, Hua Fang, Jiao YongGeng, Qin ErYun, Zhi YiXiao, Pang MengYuan, Xu HongQin, Chi XiuMei, Niu JunQi, Hua Rui. Serum level of ceruloplasmin in patients with different liver diseases in Jilin,China[J]. Journal of Clinical Hepatology, 2020, 36(9): 2025-2029. doi: 10.3969/j.issn.1001-5256.2020.09.023 |
[14] | Chen ShuRu, Chong YuTian, Li XinHua. Pathogenic mechanism and clinical diagnosis of hereditary abnormal copper metabolism[J]. Journal of Clinical Hepatology, 2019, 35(8): 1667-1672. doi: 10.3969/j.issn.1001-5256.2019.08.003 |
[15] | Yu PengFei, Wu Qiao, Duan ZhongPing, Chen Yu. Research advances in the mechanism of drug-induced liver injury due to paracetamol[J]. Journal of Clinical Hepatology, 2019, 35(9): 2108-2112. doi: 10.3969/j.issn.1001-5256.2019.09.050 |
[16] | Chen Xiang, Wen DiGuang, You Yu, Gong JianPing. Role and mechanism of ferroptosis in treatment of liver cancer with sorafenib[J]. Journal of Clinical Hepatology, 2019, 35(10): 2316-2319. doi: 10.3969/j.issn.1001-5256.2019.10.040 |
[17] | Bao SuXia, Zheng JianMing, Shi GuangFeng. Research progress in association between interleukin-23 and liver diseases[J]. Journal of Clinical Hepatology, 2016, 32(2): 393-396. doi: 10.3969/j.issn.1001-5256.2016.02.044 |
[18] | Lu: XinPing, Wu Jing, Chen JingTao. Application of antibody preparation technology based on single B lymphocytes in liver diseases[J]. Journal of Clinical Hepatology, 2015, 31(12): 2104-2109. doi: 10.3969/j.issn.1001-5256.2015.12.028 |
[19] | Huang LanYu, Xu LieMing. Relationship between liver diseases and autophagy[J]. Journal of Clinical Hepatology, 2014, 30(2): 186-188. doi: 10.3969/j.issn.1001-5256.2014.02.022 |
[20] | Liu GuoWang, Cao WuKui. Application of stem cells in liver disease treatment[J]. Journal of Clinical Hepatology, 2011, 27(9): 999-1002. |
1. | 郭新华,王佳慧,段雪琳,彭岳,赵铁建,郑洋,赵斌. 金属离子代谢:慢性肝病中医药防治新思路. 临床肝胆病杂志. 2024(07): 1498-1504 . ![]() | |
2. | 董昌君,张先林. 铜死亡在肝细胞癌发病机制中的研究进展. 中国普通外科杂志. 2024(07): 1172-1179 . ![]() | |
3. | 刘诗卉,李冬冬,张宏坤,刘传苗,吴执竞,赵文. 细胞死亡在NAFLD发生发展中的研究进展. 齐齐哈尔医学院学报. 2024(16): 1578-1582 . ![]() | |
4. | 朱明强,谢星,廖启成,何晓,丁佑铭,王小华. 铜死亡的发生机制及在肝脏疾病中的作用. 临床肝胆病杂志. 2024(11): 2332-2337 . ![]() |